News
SMTI
22.79
-4.20%
-1.00
Weekly Report: what happened at SMTI last week (0518-0522)?
Weekly Report · 5d ago
Sanara MedTech Signals Profitable Growth Momentum
TipRanks · 05/20 07:45
Weekly Report: what happened at SMTI last week (0511-0515)?
Weekly Report · 05/18 10:00
Sanara MedTech: From Cash Burner To Profitable Growth
Seeking Alpha · 05/14 17:50
Sanara MedTech Earnings Call Signals Profitable Growth
TipRanks · 05/13 00:38
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 05/12 17:06
Sanara outlines Q2 2026 net revenue of $28.5M-$29.5M while reaffirming $116M-$121M full-year outlook
Seeking Alpha · 05/12 14:51
Sanara MedTech reports Q1 EPS 4c vs. (7c) last year
TipRanks · 05/12 13:34
Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Personalis (PSNL)
TipRanks · 05/12 13:10
Transcript: Sanara MedTech Q1 2026 Earnings Conference Call
Benzinga · 05/12 12:23
Sanara MedTech Sees Q2 Sales $28.500M-$29.500M vs $28.650M Est
Benzinga · 05/11 21:19
Sanara MedTech Affirms FY2026 Sales Guidance of $116.000M-$121.000M vs $117.300M Est
Benzinga · 05/11 21:18
Sanara MedTech Q1 revenue rises, swings to profit
Reuters · 05/11 21:01
Sanara MedTech GAAP EPS of $0.04, revenue of $27.8M
Seeking Alpha · 05/11 20:58
*Sanara MedTech Backs 2026 Rev $116M-$121M >SMTI
Dow Jones · 05/11 20:52
*Sanara MedTech Sees 2Q Rev $28.5M-$29.5M >SMTI
Dow Jones · 05/11 20:52
*Sanara MedTech 1Q Rev $27.8M >SMTI
Dow Jones · 05/11 20:51
*Sanara MedTech 1Q EPS 5c >SMTI
Dow Jones · 05/11 20:51
*Sanara MedTech 1Q Cont Ops EPS 4c >SMTI
Dow Jones · 05/11 20:51
Sanara Q1 FY26 net income turns to USD 397,687; revenue rises 19% to USD 27.8 million
PUBT · 05/11 20:50
More
Webull provides a variety of real-time SMTI stock news. You can receive the latest news about Sanara Medtech Inc through multiple platforms. This information may help you make smarter investment decisions.
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.